Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 6 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Sacubitril/valsartan cost-effective for HFREF patients

04 Oct 2020

Switching to sacubitril/valsartan is a cost-effective treatment option for patients with heart failure with reduced ejection fraction (HFREF), a recent Australia study has found.

The researchers constructed a decision analytic transition Markov model that compared the health effects and economic requirements of using sacubitril/valsartan (200 mg twice daily) vs enalapril (10 mg twice daily), a common reference standard. The model had yearly cycles and its population included 1,000 HFREF patients, assumed to be 63 years of age at entry.

The model had two health states (alive with HFREF and dead), and four transition states, which could occur in any order: “no HF hospitalization, stay alive,” “nonfatal hospitalization for HF,” “CV death,” and “non-CV death.” Over a time horizon of 20 years, the model assessed the incremental cost-effectiveness ratio (ICER), in Australian dollars, per years of life saved (YoLS) and per quality-adjusted life-years (QALY) gained.

Most of the participants died by the end of the 20-year projection, with <5 percent left surviving. Patients in the sacubitril/valsartan group were modelled to live an average of 5.36 years and 3.70 QALYs, while the corresponding values for the enalapril group were 4.92 years and 3.39 QALYs.

The sacubitril/valsartan patients incurred total treatment and disease-related costs of A$14,128,566 and A$6,150,973, respectively, totalling A$ 20,279,538. In comparison, the costs in the enalapril group were A$1,741,735, A$6,334,631, and A$8,076,366, respectively.

The resulting ICERs were A$27,954 per YoLS and A$40,513 per QALY gained, which “is comparable to other guideline-directed medical therapies in HF,” the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 6 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.